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ABSTRACT  
Objective  
To explore the effect of comedication with conventional synthetic disease modifying antirheumatic 
drugs (csDMARDs) on drug retention and clinical effectiveness of tumour necrosis factor inhibitors 
(TNFi) in patients with axial spondyloarthritis (axSpA). 
Methods  
Inclusion of all patients starting treatment with a TNFi in a large prospective axSpA cohort (SCQM-
axSpA). Crude drug retention was analyzed using the Kaplan Meier method and in adjusted analyses 
we used Cox proportional hazard regression to model TNFi discontinuation. We evaluated multiple 
disease activity measures and validated clinical response criteria over time.  
Results 
A total of 2765 TNFi treatment courses were included from 1914 axSpA patients, with 20.4% in 
combination with a csDMARD.  In unadjusted analyses, the monotherapy group had significantly 
shorter median TNFi retention time (32.7 months), compared to the co-therapy group (39.1 months) 
(p= 0.04).  In multivariate adjusted analyses, the monotherapy group had significantly lower TNFi 
retention, with a hazard ratio (HR) of 1.17 (95%CI: 1.01;1.35). This effect was even larger when 
considering only Infliximab treated patients, with a HR for monotherapy of 1.36 (95%CI: 1.06;1.74). 
Clinical response rates were almost identical at 1 year with a change in the Bath Ankylosing 
Spondylitis Disease Activity Index of -2.02 and -2.00 (p=0.83) and a change in the Ankylosing 
Spondylitis Disease Activity Score using CRP of -1.14 and -1.12 (p=0.45) in the monotherapy and co-
therapy groups respectively. 
Conclusion 
We demonstrate an association between the combination of a TNFi with csDMARDs and improved 
drug retention in axSpA patients, particularly in the subgroup of patients with Infliximab. 
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MANUSCRIPT 
 
The efficacy of tumour necrosis factor inhibitors (TNFi) in the management of ankylosing spondylitis 
(AS), in patients for whom treatment with non-steroidal anti-inflammatory drugs (NSAIDs) is 
inadequate, has been clearly demonstrated in numerous randomised controlled trials (RCT) (1-5). 
The combination of a TNFi with a conventional synthetic disease modifying antirheumatic drug 
(csDMARD) such as Methotrexate (MTX) is undeniably associated with a lower risk of TNFi 
discontinuation compared with TNFi monotherapy in rheumatoid arthritis (RA) (6). In psoriatic 
arthritis (PsA), improved TNFi retention has been described when associated with csDMARDs (7-10), 
although several RCTs did not demonstrate any advantage of co-therapy with MTX in terms of clinical 
efficacy (11-12). The majority of registry studies and pharmacokinetic studies of AS patients have not 
demonstrated any benefit of csDMARD therapy in association with TNFi (7, 13-16), although a recent 
publication from the ARTIS cohort reported better 5-year drug retention with a first TNFi when given 
in combination with a csDMARD(17).  
 
Although the majority of axial spondyloarthritis (axSpA) patients respond very well to TNFi, up to 40% 
fail to reach an acceptable level of clinical efficacy (18-19). One possible explanation could be the 
formation of TNFi-neutralizing antibodies which may decrease serum drug levels and subsequently 
result in loss of efficacy. Alternatively, other pathogenic mechanisms or cytokine pathways, besides 
TNF, may also be involved. Concomitant use of csDMARDs such as MTX may improve the efficacy of 
TNFi by targeting other pathways and reducing immunogenicity, thus preventing secondary loss of 
efficacy. This is of particular significance in axSpA, as there are fewer classes of biologic agents to 
switch to in the event of treatment failure, in comparison with RA. Observational data from registries 
reveal a high frequency of csDMARD use, both as monotherapy and in combination with TNFi in AS 
patients, with rates of up to 61% (20-22). 
 
One striking difference between axSpA and RA is that csDMARDs are clearly effective as 
monotherapy in RA, whereas their efficacy as monotherapy has not been demonstrated in axSpA (23-
25).  Current international Assessment of SpondyloArthritis international Society (ASAS) / EUropean 
League Against Rheumatism (EULAR) recommendations do not suggest any role for csDMARDs in 
patients with axSpA when used in combination with TNFi (26-27). Several European Rheumatology 
societies suggest a potential role for immunosuppressive therapy (without precision of which agent) 
in the treatment of AS patients taking Infliximab (IFX), with the rationale of preventing or reducing 
the development of anti-IFX antibodies (28).  
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Thus, despite the lack of convincing evidence for a role for csDMARDs in combination with TNFi in 
patients with axSpA, a large percentage of physicians continue to prescribe this combination. 
Therefore, we sought to further explore evidence for a potential benefit of csDMARDs in 
combination with TNFi in patients with axSpA in a large prospective cohort. 
 
Patients and methods 
Study population and design 
The “Swiss Clinical Quality Management” (SCQM) registries monitor disease activity, radiographic 
damage, patient characteristics and various symptom questionnaires at regular intervals in patients 
with RA, axSpA, PsA and undifferentiated arthritis Inclusion of patients into the database is based on 
expert attending Rheumatologist opinion. Clinical and laboratory data are collected annually with the 
possibility to include additional data at intermediate visits (29). Ethical approval for the collection of 
patient data was given by the national review board. Informed consent was obtained from all 
patients at inclusion in the registry. Management decisions after inclusion into SCQM were left 
entirely to the discretion of the treating rheumatologist.  
 
AxSpA patients recruited in the ongoing SCQM registry are required to have a clinical diagnosis of AS 
or anoth r form of SpA with predominantly axial disease according to the treating rheumatologist 
(30). Patients with psoriatic arthritis, including those with axial involvement are included in a 
separate cohort. This was a longitudinal study within the SCQM-axSpA cohort analyzing data 
collected between January 2005 and August 2013.  
 
The following minor modifications were required as the cohort was initiated prior to publication of 
the ASAS criteria: the ASAS criterion “ inflammatory back pain” was defined as low back pain and 
morning stiffness for >3 months, improving with exercise but not relieved by rest, as well as age at 
onset <45 years. Furthermore, the ASAS criterion “good response to NSAIDs” was only added to the 
questionnaire in 2009. Inclusion criteria included the initiation of a TNFi after recruitment into the 
cohort (or within a month prior to inclusion in the registry) and at least one follow-up visit on the 
respective TNFi. Exclusion criteria included TNFi initiation more than 1 month prior to inclusion in the 
registry and missing follow-up assessments. 
 
Outcomes and exposures 
The study’s predefined primary outcome of interest was the rate of TNFi retention of combined 
therapy with csDMARDs and TNFi agents (co-therapy), compared with TNFi monotherapy. The 
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exposure of interest was the presence or absence of concomitant csDMARD use at baseline (BL) in 
association with the TNFi. Secondary outcomes of interest were the longitudinal evolution of disease 
activity as measured by the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) (31) and the 
Ankylosing Spondylitis Disease Activity Score using CRP (ASDAS-CRP) (32) after initiation of a TNFi.  
The following clinical response variables were also assessed at 12 months: 50% improvement in the 
BASDAI (BASDAI50), ASDAS inactive activity (ASDAS-ID), ASDAS clinically important improvement 
(ASDAS-CII)  and the ASAS criteria for 20% and 40% improvement (ASAS20 and ASAS40) (29). We 
explored potential effect modification by the type of TNFi (infliximab versus humanized TNFi), 
presence of positive classification criteria (Modified New York Criteria (MNYc) and ASAS axSpA 
criteria), smoking and the presence of peripheral joint involvement. Response outcomes based on 
the proportion of patients adhering to TNFi therapy, according to the LUND Efficacy indeX (LUNDEX) 
were also calculated (33). 
 
Statistical analysis 
All analyses were planned a priori and no correction for multiple testing was performed. Regarding 
the baseline characteristics, categorical variables were compared between patients with TNFi as 
monotherapy and patients treated with one or more csDMARDs in association with a TNFi using the 
Chi-squared test. We utilized standard descriptive statistics to test for differences in mean values. In 
the cases with non-symmetrically distributed variables, the Mann-Whitney test was utilized. All tests 
were two-sided, with a significance level set at 5%. 
 
We chose TNFi retention as the primary outcome as drug retention rates indicate both the patient’s 
and the doctor’s satisfaction with therapy and provide a global measure of the overall treatment 
effectiveness and tolerability. The Kaplan Meier method was utilized to obtain the graphical 
representation of drug discontinuation over time. In adjusted analyses, we used Cox proportional 
hazard regression to model TNFi discontinuation with adjustments for potential confounders (age at 
baseline, sex, disease duration at baseline, education level (as a proxy of socio-economic status), 
presence of ASAS axSpA classification criteria, elevated CRP at baseline, smoking status, calendar 
year initiation of TNFi (<2008, > 2011) and number of TNFi used). Andersen-Gill Cox models were 
utilized to account for multiple TNFi discontinuations in the same patient.  
 
We investigated effect modification for positive MNYC, positive ASAS criteria, the presence of 
peripheral joint involvement and smoking in terms of monotherapy versus co-therapy. In addition, 
sensitivity analyses with the different classification criteria (Rheumatologist diagnosis, MNYC and 
ASAS) were performed.  
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The baseline visit was defined as an available visit within 3 months prior to TNFi initiation and up to 1 
month following the start of the TNFi agent. When clinical outcome measures were unavailable at 12 
months (+/- 3 months), we used longitudinal interpolation with mixed-effects linear regression to 
impute missing values. This imputation was required by the structure of SCQM data, as the yearly 
control visit does not necessarily match yearly intervals after initiation of treatment. A mixed-effects 
model for longitudinal data was used to analyze disease activity (BASDAI and ASDAS-CRP) over time. 
Mixed-effects models with per patient random intercept and random slope were used to analyze 
BASDAI50, ASDAS-CII, ASDAS-ID and ASAS20/40. Adjustments were made for potential confounders 
as described above. Stata statistical software (StataCorp LP, version 11.1) was used for all analyses. 
 
Results:  
Patient disposition and characteristics 
A total of 1914 axSpA patients were included in the analyses for a total of 2765 TNFi treatment 
courses (Table 1).  At baseline 55.3% were males with a mean age of 41.7 years (+/- 12.0), a median 
disease duration of 8.3 years [IQR: 3.0, 15.9] and a median follow-up of 5.0 years [IQR: 2.8, 7.3]. A 
total of 565 (20.4%) of the TNFi treatment courses were as co-therapy with a csDMARD (MTX 77.2%, 
Sulfasalazine (SSZ) 21.2%, Leflunomide (LEF) 8.3% and other csDMARDs 1.6%). The mean MTX dose 
was 13.6 mg (SD 5.0) per week and the mean SSZ dose was 1.8 g (SD 0.5) per day. The TNFi 
prescribed was infliximab (IFX) in 26.1%, adalimumab (ADA) in 33.3%, etanercept (ETN) in 27.5%, 
golimumab (GOL) in 12.3% and certolizumab pegol (CER) in 0.8%.  
 
Co-therapy patients were less likely to be HLA-B27 positive (62.1% vs. 67.0%, p=0.046), more likely to 
present with peripheral joint manifestations (72.2% vs. 52.7%, p<0.001), less likely to be ASAS criteria 
positive (65.3% vs. 80.6%, p<0.001) and had a longer median follow-up (6.0 vs. 4.7 years, p<0.001). In 
addition, co-therapy patients were significantly more likely to be treated with IFX and significantly 
less likely to be treated with ADA, ETN or GOL. At 12 months, 62.0% of the co-therapy group 
remained on a csDMARD and 10.8% of the monotherapy group had commenced a csDMARD. There 
was a significant reduction in the use of csDMARD co-therapy in the overall cohort over the 3 time-
periods of prior to 2008, 2008-2011 and after 2011, of 26.2%, 20.3% and 14.5% respectively.  
 
Drug retention 
 In unadjusted analyses of all TNFi treatment courses, the median TNFi retention time was 33.9 
months. There was a significantly longer median TNFi retention time in the co-therapy group, 
compared with the monotherapy group (39.1 months versus 32.7 months respectively, p=0.04). 
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When considering only the first TNFi treatment course, the median TNFi retention time was  36.3 
months. Regarding drug retention in patients treated with IFX, there was a significant difference 
between the co-therapy and the monotherapy groups, with median TNFi retention times of 51.9 
months and 30.4 months respectively (p=0.02). No significant differences were demonstrated with 
the other TNFi. 
 
In multiple adjusted analyses corrected for potential confounding factors, we found a significantly 
shorter TNFi retention in monotherapy patients with a HR of 1.17 (95%CI: 1.01; 1.35) (Figure 1A). 
When considering only IFX patients, there was an even greater benefit of co-therapy with regards to 
TNFi retention with a HR for monotherapy of 1.36 (95%CI: 1.06; 1.74) (Figure 1B), which was not 
apparent with the other TNFi.  
 
Significant predictors for greater TNFi retention were male sex (p<0.001), the presence of positive 
ASAS criteria (p=0.03), raised CRP levels at baseline (p=0.008) and shorter disease duration at 
baseline (p=0.009). There was no evidence of effect modification in terms of monotherapy versus co-
therapy for positive MNYC, positive ASAS criteria or peripheral joint involvement. However, there 
was effect modification with regards to smoking (HR 0.72, 95%CI: 0.54; 0.97). The TNFi retention 
advantage with co-therapy was lost in smokers, whereby non-smokers with co-therapy had a 
significantly greater TNFi retention than smokers with co-therapy (p=0.003) (Figure 2). The previously 
described improved TNFi retention with csDMARDs in patients treated with IFX was not observed in 
the subgroup of current smokers treated with IFX. 
 
The sensitivity analyses restricting the sample to patients fulfilling the ASAS criteria revealed very 
similar hazard ratios, whereby the monotherapy group demonstrated a strong trend towards lower 
TNFi retention with a HR of 1.22 (95%CI: 0.99; 1.51) for all patients, and a HR of 1.35 (95%CI: 0.97; 
1.88) in the subgroup of patients treated with Infliximab. 
 
Regarding the reasons for TNFi discontinuation, there were no significant differences between the 
monotherapy and co-therapy groups (p = 0.20), particularly with regards to adverse events (24.3% 
and 25.0% respectively) (Table 1). Although, there was a slightly higher (non-significant) rate of 
remission in the combination group (5.9% vs. 3.2%).    
 
Clinical response rates  
There were no significant differences between the monotherapy and co-therapy groups with regards 
to change in BASDAI score over the first year (p=0.83), nor with change in ASDAS-CRP scores over the 
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first year (p=0.45) (Table 2). This effect remained constant in specific sub-groups (ASAS positive, 
MNYc positive, non-radiographic axSpA (nr-axSpA), first TNFi only, IFX patients and patients with 
peripheral involvement) (Table 2). Overall, patients with their first TNFi and patients with positive 
MNY or ASAS criteria demonstrated greater improvements in BASDAI and ASDAS-CRP scores, 
whereas patients with nr-axSpA responded less well. 
 
We found no significant differences between the monotherapy and co-therapy groups with regards 
to BASDAI50, ASDAS-CII, ASAS20 and ASAS40 at 1 year (Table 3). However, more patients in the 
monotherapy group obtained an ASDAS-ID (15.1% vs. 9.5%, p=0.01) than in the co-therapy group. 
When we adjusted the ASDAS-ID response outcomes by the proportion of patients adhering to TNFi 
therapy, according to the LUNDEX, the differences between groups were less pronounced (Table 3). 
 
In the subgroup of patients treated with IFX, the majority of the clinical outcome variables were 
numerically superior in the co-therapy group compared to the monotherapy group, and the ASDAS-
CII was significantly greater in the co-therapy group (60.5% vs. 49.3%, p=0.02). In ASAS positive IFX-
treated patients, there was a significantly greater improvement in the ASDAS-CRP in the co-therapy 
group compared with the monotherapy group (-1.30 vs. -1.14, p=0.040). We repeated the analyses 
investigating clinical outcomes at 24 months and found that the change in BASDAI was -1.839 in the 
monotherapy group and -1.837 in the co-therapy groups (p=0.97).  
 
Discussion 
This longitudinal study of a large cohort of patients with axSpA demonstrates improved TNFi 
retention in patients treated with csDMARDs in combination with the TNFi. The overall survival 
advantage appears to be uniquely due to a benefit in the subgroup of patients treated with IFX.   
 
A potential benefit for the use of csDMARDs in association with TNFi in axSpA has been hypothesized 
due to an established benefit in RA patients and a possible reduction in anti-TNF antibody formation. 
An independent anti-inflammatory effect of the csDMARD in AS appears not to exist, at least not for 
MTX, which has been evaluated in three RCTs, with a Cochrane review concluding that there was 
“not enough evidence to support any benefit of MTX in the treatment of AS” (23).  
 
A reduced clinical response to IFX treatment in AS patients has been demonstrated to correlate with 
the formation of anti-IFX antibodies (34). In PsA patients, Fagerli et al found a significant benefit of 
MTX in combination with IFX in terms of TNFi drug retention, but not with ADA or ETN (9). In another 
study of PsA patients, there was no benefit of MTX in combination with ETN (35). In axSpA patients 
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from the Czech ATTRA cohort, no benefit was observed with csDMARDs given in combination with 
ADA with regards to either drug retention or the probability of reaching low disease activity 
(36).Conversely, Lie et al found a significant advantage in terms of TNFi retention with MTX co-
therapy in ADA, ETN and IFX-treated AS patients, but no difference with regards to undifferentiated 
SpA for all 3 agents (17).   
 
In contrast to the drug retention data, the co-therapy group did not demonstrate any advantages 
over TNFi monotherapy in terms of clinical effectiveness. Obviously drug retention reflects a 
combination of efficacy and tolerability, as well as patient and practitioner preferences. One possible 
explanation for this discrepancy is that patients on concomitant csDMARDs present fewer TNFi-
related side-effects resulting in improved drug retention without demonstrating a significant benefit 
in terms of clinical effectiveness. Nevertheless, we found no significant differences between the 2 
groups with regards to the reasons for TNFi discontinuation, including adverse events.         
 
A systematic review of RCTs and observational studies of TNFi plus MTX versus TNFi monotherapy in 
patients with PsA was recently conducted (37). The results from the RCTs did not find any differences 
in efficacy for peripheral joint disease. Similarly, data from three European biologics registries did not 
demonstrate any major differences in efficacy, although there was evidence of benefit with regards 
to TNFi drug survival for patients on combination therapy.  
 
Another potential explanation for difference between outcomes is that drug retention is measured 
over time, while the clinical response rates were measured at 1 year. The 1 year mark was chosen as 
the majority of improvement in the clinical response variables occurred during the first 12 months 
with little change thereafter. Nevertheless, we repeated the analyses investigating clinical outcomes 
at 24 months and the results were quantitatively similar.  The decision to cease TNFi therapy because 
of clinical inefficacy or an adverse event in this observational study was at the discretion of the 
treating rheumatologist and was not subject to study protocol. It is therefore unlikely that there was 
any bias in the way such decisions were made between the 2 treatment groups. 
 
A significantly higher proportion of patients obtained the ASDAS-ID outcome in the monotherapy 
group compared with the co-therapy group. Although statistically significant, this small difference is 
unlikely to be clinically relevant. When the proportion of patients adhering to TNFi therapy was taken 
into account with the use of the LUND Efficacy indeX (ASDAS-ID LUNDEX) these differences 
disappeared. 
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The response rates of certain variables such as the ASAS40 were somewhat lower than those seen in 
other trials. Only 8% of patients in this cohort demonstrated a ≥ 40% improvement in BASFI scores at 
1 year, which limited the ASAS40 response rates. This may be related to a relatively high age and long 
disease duration in our study population, as well as the inclusion of multiple TNFi treatment courses.  
 
There are certain well known limitations to comparing treatment outcomes based on observational 
data, as the decision to treat patients is not entirely random, but is dependent upon numerous 
variables. Despite the fact that our results are very similar following correction for a large number of 
potentially confounding variables, the possibility remains of residual confounding by indication, 
which may have affected the response. There are a number of reasons why this seems unlikely. 
Firstly, the 2 groups were well matched in terms of age, sex, socio-economic status, disease duration, 
CRP and smoking status. Secondly, there were no significant differences between the groups in terms 
of disease activity, determined by the BASDAI and the ASDAS-CRP. Thirdly, there were differences 
observed in the proportion of patients in each group in terms of the specific TNFi prescribed, with 
patients more likely to be in the co-therapy group with IFX and more likely to be in the monotherapy 
group with ADA, ETN and GOL. Nevertheless, there is no convincing evidence that there is a 
difference in efficacy between the various TNFi, and thus this prescribing difference is unlikely to 
have had an effect on the outcomes.  
 
Although the monotherapy and co-therapy groups were well matched, there were significant 
differences with regards to peripheral arthritis, HLA-B27 positivity and positive ASAS criteria. As the 
HLA-B27 status was unknown for 16.1% of treatment courses (15.4% of patients), this variable was 
not included in the initial model. We repeated the analyses including only patients with known HLA-
B27 status and the results were quantitatively similar (data not shown). 
 
In the overall population 77.6% of patients were ASAS criteria positive and 70.4% of patients were 
MNYC criteria positive. The ASAS criteria could not be determined for 22.2% of the treatment 
courses due to absent MRI or unknown HLA-B27 status. It is possible that these investigations were 
preferentially not performed in patients with a typical presentation of axSpA. If we assume that these 
patients with missing classification status were ASAS criteria positive, the overall rate of ASAS 
positivity increases to 82.6%, which is very similar to the 82.9% sensitivity of the ASAS classification 
criteria (38).  
 
In order to determine whether the differences observed in TNFi retention between the 2 groups 
were due to the incomplete matching of several baseline variables, we performed propensity score 
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matching. We obtained two subgroups of 379 patients each that were better matched, in terms of 
peripheral arthritis, HLA-B27 positivity and the duration of follow-up (See Supplementary Table 1). In 
this propensity matched sample, the monotherapy group had a somewhat lower TNFi retention with 
a HR of 1.14 (95% CI: 0.93; 1.40), which is qualitatively similar to the HR of 1.17 demonstrated in the 
initial multiple adjusted analyses. The loss of statistical significance is probably due to the much 
smaller sample size resulting from this type of analysis.  When including only those patients treated 
with infliximab, the HR was 1.47 (95% CI: 1.06; 2.03).   
 
We defined the co-therapy group as those on at least one csDMARD at the time of TNFi initiation. 
Not taking into account the minority of patients that subsequently ceased the csDMARD is unlikely to 
have had an effect on our results. Indeed Lie et al reported that in sensitivity analyses of drug 
retention in patients with AS, there were similar results in those stopping the csDMARD at the time 
of TNFi introduction and those continuing the csDMARD (17). 
 
There are a number of strengths to our current study. Our population originated from a national 
prospective cohort of patients with axSpA, and consequently, the outcomes reflect the experience of 
the patients themselves and of their rheumatologists, as they occurred. In many observational 
studies the classification criteria are not available, whereas we had this information for the majority 
of our patients. Many studies are limited to a subset of the axSpA population, such as those with 
MNYC or ASAS positive classification criteria. We investigated all subgroups, including those patients 
with nr-axSpA and those with consultant rheumatologist defined axSpA but missing imaging or HLA-
B27 status. The fact that we demonstrated the same outcomes regardless of the classification 
utilized strengthens the robustness of these findings. No restrictions were made to our study 
population in terms of classification criteria or disease activity, so this cohort is truly representative 
of the group of patients that we see in our hospital based clinics and community-based consulting 
rooms on a daily basis (39).  
 
Despite not having access to the percentage of patients in this cohort with positive CASPAR criteria, it 
is very unlikely that there were a significant number of PsA patients incorrectly classified as axSpA. 
Firstly, there is a separate cohort for PsA patients, and secondly, as the rate of a past or present 
history of psoriasis in our cohort was 10.9%, which is very similar to the rate of 9.3% found in a 
systematic review and meta-analysis of the prevalence of extra-articular manifestations in AS (40). 
 
Moreover, we controlled for a large number of potentially confounding variables, including smoking 
(current and past), which has generally not been included in other cohorts. This is an important 
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point, as smoking has been shown to be associated with an impaired response to TNFi in axSpA (41). 
Indeed, we found that the TNFi retention advantage of combination with a csDMARD was absent in 
smokers, both in the overall cohort and in the subgroup of patients on IFX. There are reports 
suggesting that smoking increases basal metabolic rate and may reduce the potency of csDMARDs 
(42). This further emphasizes the importance of encouraging smoking cessation in axSpA patients. 
Finally, the fact that we demonstrate almost identical results with a propensity-matched sample and 
in sensitivity analyses limited to ASAS criteria positive patients, further reinforces the validity of our 
findings. 
 
In conclusion, we demonstrate an association between co-therapy with a TNFi and csDMARDs and 
improved drug retention in axSpA patients. The overall survival advantage appears to be uniquely 
due to a benefit in the subgroup of patients treated with IFX. Regarding clinical effectiveness, co-
therapy was not significantly superior to TNFi monotherapy. Higher rates of TNFi retention were seen 
in males and in patients with shorter disease duration, positive classification criteria and raised CRP 
levels. Consequently, there may be a role for the use of csDMARDs in axSpA patients treated with 
IFX, particularly in non-smokers. 
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Table and Figure legends: 
 
Figure 1.  Adjusted TNF inhibitor retention curves for monotherapy (Mono) and co-therapy (Comb) 
groups using a Cox proportional hazard model; (A) for all patients and (B) for patients treated with 
Infliximab. The tables show the number of patients at risk at baseline (0), 1, 2, 3, 4 and 5 years in 
each group. HR = hazard ratio. 
 
Figure 2. Adjusted TNF inhibitor retention curves for monotherapy (MONO) and co-therapy (COMB) 
groups in smokers and non-smokers using a Cox proportional hazard model. The p-value relates to 
non-smokers in the co-therapy group versus smokers in the co-therapy group. 
 
Table 1. Baseline characteristics of patients with axSpA classified by treatment with TNFi 
monotherapy verses TNFi in association with a csDMARD (co-therapy) including all treatment 
courses. Except where indicated otherwise, values are the mean (± standard deviation). N = 
number. TNFi = tumour necrosis factor inhibitor; axSpA = axial spondyloarthritis; IQR = Inter 
Quartile Range; BASDAI = Bath Ankylosing Spondylitis Disease Activity Index; BASFI = Bath 
Ankylosing Spondylitis Functional Index; ASDAS-CRP = Ankylosing Spondylitis Disease Activity 
Score using CRP (C-reactive protein) levels. 
 
Table 2. Change in BASDAI and ASDAS-CRP scores after 1 year of treatment with TNFi in patients with 
axSpA classified by TNFi monotherapy versus co-therapy in the different subgroups. Mono = 
monotherapy (TNFi alone); Comb = Co-therapy (TNFi + ≥ 1 DMARD); BASDAI = Bath Ankylosing 
Spondylitis Disease Activity Index; ASDAS-CRP = Ankylosing Spondylitis Disease Activity Score using 
CRP (C-reactive protein) levels; TNFi = Tumor Necrosis Factor inhibitors; axSpA = axial 
spondyloarthritis; ASAS = Assessment of SpondyloArthritis international Society; MNYc = modified 
New York classification criteria for ankylosing spondylitis; nr-axSpA = non-radiographic axial 
spondyloarthritis; IFX = Infliximab. 
 
Table 3. Response rates after 1 year of treatment with TNFi in patients with axSpA classified by TNFi 
monotherapy versus co-therapy including all treatment courses. Except where indicated otherwise, 
values are percentages. TNFi = Tumor Necrosis Factor inhibitors; axSpA = axial spondyloarthritis; 
LUNDEX = LUND Efficacy indeX; ASAS = Assessment of SpondyloArthritis international Society; 
BASDAI50 = 50% improvement in the Bath Ankylosing Spondylitis Disease Activity Index; ASDAS = 
Ankylosing Spondylitis Disease Activity Score; ASDAS-CII = ASDAS clinically important improvement; 
ASDAS-ID = ASDAS inactive disease; ASAS20 = 20% improvement according to ASAS; ASAS40 = 40% 
improvement according to ASAS. 
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Table 1: Baseline characteristics of patients with axSpA classified by treatment with TNFi 
monotherapy verses TNFi in association with a csDMARD (co-therapy) including all 
treatment courses. 
 
Characteristic N Monotherapy 
N=2200 
Co-therapy 
N=565 
p 
Age (years) 2765 41.5 ± 11.9 42.5 ± 12.3 0.07 
Gender (%, male)  2765 55.0 56.5 0.55 
Weight (kg) 2611 74.0 ± 15.1 74.9 ± 16.0 0.20 
Height (cm) 2570 170.5 ± 9.4 170.9 ± 8.8 0.33 
Higher education (%)  2765 26.1 27.1 0.63 
Disease duration (years)[median, IQR] 2655 8.4 [3.1,16.3] 8.2 [2.7,15.0] 0.15 
Peripheral arthritis (%) 2765 52.7 72.2 <0.001 
Ever psoriasis (%) 2261 10.8 11.3 0.77 
Follow-up (years) )[median, IQR] 2765 4.7 [2.6,6.9] 6.0 [3.8,7.9] <0.001 
HLA-B27 (% positive)  2321 67.0 62.1 0.046 
CRP at baseline (mg/l) )[median, IQR] 1642 7.0 [2,10] 6.0 [3,11] 0.12 
Ever Smoker (%) 2542 60.0 56.3 0.13 
MNYC positive (%) 1909 71.0 67.6 0.19 
ASAS axSpA positive (%) 2152 80.6 65.3 <0.001 
BASDAI 2100 5.04 ± 1.94 5.10 ± 1.89 0.58 
BASFI  2090 3.78 ± 2.35 4.01 ± 2.42 0.07 
ASDAS-CRP 1972 3.08 ± 0.93 3.17 ± 0.85 0.10 
TNFi :     
Infliximab (%)   722 23.3 37.2 <0.001 
Adalimumab (%)   922 34.4 29.0 0.02 
Etanercept (%)   759 28.5 23.2 0.01 
Golimumab (%)  339 13.0 9.5 0.03 
Certolizumab (%) 23 0.8 1.1 0.50 
TNFi discontinuation (N):  1006 272 0.20 
Adverse events (n, %)  244 (24.3) 68 (25.0)  
Remission (n, %)  32 (3.2) 16 (5.9)  
Other reasons (n, %)  253 (25.1) 65 (23.9)  
Ineffectiveness (n, %)  477 (47.4) 123 (45.2)  
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Table 2. Change in BASDAI and ASDAS-CRP scores after 1 year of treatment with TNFi in patients with 
axSpA classified by TNFi monotherapy versus co-therapy in the different subgroups. 
 
 BASDAI ASDAS-CRP 
 N Mono Comb P N Mono Comb P 
All treatment courses 1928 -2.02 -2.00 0.83 1967 -1.14 -1.12 0.45 
ASAS criteria positive 1215 -2.05 -2.15 0.29 1248 -1.15 -1.21 0.22 
MNYc positive 1042 -2.03 -2.10 0.45 1093 -1.16 -1.20 0.42 
nr-axSpA 151 -1.98 -1.96 0.92 174 -1.09 -1.16 0.53 
1st TNFi 1365 -2.15 -2.17 0.82 1446 -1.22 -1.20 0.64 
IFX patients 503 -2.01 -2.08 0.50 514 -1.10 -1.19 0.21 
Peripheral involvement 1081 -2.01 -1.96 0.49 1091 -1.13 -1.09 0.39 
1st TNFi and MNYc pos 738 -2.21 -2.29 0.52 792 -1.27 -1.28 0.75 
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Table 3. Response rates after 1 year of treatment with TNFi in patients with axSpA classified 
by TNFi monotherapy versus co-therapy including all treatment courses. 
 
 N Monotherapy Co-therapy P 
BASDAI50 1928 28.6 25.0 0.11 
BASDAI50 LUNDEX  19.0 18.6  
ASDAS-CII 1563 50.7 51.7 0.73 
ASDAS-CII LUNDEX  33.7 38.5  
ASDAS-ID 1913 15.1 9.5 0.01 
ASDAS-ID LUNDEX  10.0 7.1  
ASAS20 1896 84.5 83.8 0.76 
ASAS 20 LUNDEX  56.2 62.3  
ASAS40 1896 19.8 19.1 0.77 
ASAS 40 LUNDEX  13.2 14.2  
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Characteristic  Monotherapy 
N=379 
Co-therapy 
N=379 
p 
Age (years)  46.5 ± 12.2 44.4 ± 12.7 0.01 
Gender (%, male)  57.3 58.3 0.83 
Weight (kg)  73.5 ± 15.2 74.8 ± 16.0 0.33 
Height (cm)  169.7 ± 9.5 170.8 ± 8.4 0.10 
Higher education (%)  23.0 22.4 0.93 
Disease duration (years)[median, IQR]  9.6 [3.2 ; 17.3] 8.9 [3.6 ; 17.3] 0.93 
Peripheral arthritis (%)  77.7 78.8 0.77 
Follow-up (years) [median, IQR]  2.5 [0.8 ; 5.4] 2.4 [0.9 ; 5.7] 0.75 
HLA-B27 (% positive)  65.3 71.0 0.13 
CRP at baseline (mg/l) )[median, IQR]  8.0 [4.0; 18.0] 8.0 [4.0; 19.0] 0.61 
Ever Smoker (%)  58.0 56.7 0.76 
MNYC positive (%) 69.6 72.9 0.42 
ASAS axSpA positive (%)  53.0 66.5 <0.001 
BASDAI  5.0 ± 2.5 4.7 ± 2.3 0.18 
BASFI 4.0 ± 2.5 3.9 ± 2.6 0.85 
ASDAS-CRP  3.8 ± 1.0 3.7 ± 1.0 0.29 
Infliximab (%)  44.1 36.2 0.03 
Adalimumab (%)  21.6 28.0 0.053 
Etanercept (%)  24.0 26.9 0.40 
Golimumab (%)  10.3 10.3 1.00 
Certolizumab (%)  1.1 0.8 1.00 
 
Supplementary Table 1. Baseline characteristics of patients with axSpA classified by treatment 
with TNFi monotherapy verses TNFi in association with a csDMARD (co-therapy) in the 
propensity matched sample. Except where indicated otherwise, values are the mean (± standard 
deviation). N = number. TNFi = tumour necrosis factor inhibitor; axSpA = axial spondyloarthritis; 
IQR = Inter Quartile Range; BASDAI = Bath Ankylosing Spondylitis Disease Activity Index; BASFI = 
Bath Ankylosing Spondylitis Functional Index; ASDAS-CRP = Ankylosing Spondylitis Disease 
Activity Score using CRP (C-reactive protein) levels. 
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Table 1: Baseline characteristics of patients with axSpA classified by treatment with TNFi 
monotherapy verses TNFi in association with a csDMARD (co-therapy) including all 
treatment courses. 
 
Characteristic N Monotherapy 
N=2200 
Co-therapy 
N=565 
p 
Age (years) 2765 41.5 ± 11.9 42.5 ± 12.3 0.07 
Gender (%, male)  2765 55.0 56.5 0.55 
Weight (kg) 2611 74.0 ± 15.1 74.9 ± 16.0 0.20 
Height (cm) 2570 170.5 ± 9.4 170.9 ± 8.8 0.33 
Higher education (%)  2765 26.1 27.1 0.63 
Disease duration (years)[median, IQR] 2655 8.4 [3.1,16.3] 8.2 [2.7,15.0] 0.15 
Peripheral arthritis (%) 2765 52.7 72.2 <0.001 
Ever psoriasis (%) 2261 10.8 11.3 0.77 
Follow-up (years) )[median, IQR] 2765 4.7 [2.6,6.9] 6.0 [3.8,7.9] <0.001 
HLA-B27 (% positive)  2321 67.0 62.1 0.046 
CRP at baseline (mg/l) )[median, IQR] 1642 7.0 [2,10] 6.0 [3,11] 0.12 
Ever Smoker (%) 2542 60.0 56.3 0.13 
MNYC positive (%) 1909 71.0 67.6 0.19 
ASAS axSpA positive (%) 2152 80.6 65.3 <0.001 
BASDAI 2100 5.04 ± 1.94 5.10 ± 1.89 0.58 
BASFI  2090 3.78 ± 2.35 4.01 ± 2.42 0.07 
ASDAS-CRP 1972 3.08 ± 0.93 3.17 ± 0.85 0.10 
TNFi :     
Infliximab (%)   722 23.3 37.2 <0.001 
Adalimumab (%)   922 34.4 29.0 0.02 
Etanercept (%)   759 28.5 23.2 0.01 
Golimumab (%)  339 13.0 9.5 0.03 
Certolizumab (%) 23 0.8 1.1 0.50 
TNFi discontinuation (N):  1006 272 0.20 
Adverse events (n, %)  244 (24.3) 68 (25.0)  
Remission (n, %)  32 (3.2) 16 (5.9)  
Other reasons (n, %)  253 (25.1) 65 (23.9)  
Ineffectiveness (n, %)  477 (47.4) 123 (45.2)  
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